The content on this site is intended for healthcare professionals only
New approaches and new partnership models for biomarker based clinical research
Overall survival update from the BREAK-3 study
Ipilimumab may improve outlook of metastatic melanoma in the elderly
ESMO 2014: News Roundup
ESMO 2014 Editor's roundup
Ipilimumab extends relapse-free survival in resectable melanoma
Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma
Nivolumab potentially superior to standard chemo in advanced melanoma
Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma
Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma
Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma
